These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 16723044

  • 41. An in vitro screening cascade to identify neuroprotective antioxidants in ALS.
    Barber SC, Higginbottom A, Mead RJ, Barber S, Shaw PJ.
    Free Radic Biol Med; 2009 Apr 15; 46(8):1127-38. PubMed ID: 19439221
    [Abstract] [Full Text] [Related]

  • 42. Amyotrophic lateral sclerosis: pathogenesis, differential diagnoses, and potential interventions.
    Patel SA, Maragakis NJ.
    J Spinal Cord Med; 2002 Apr 15; 25(4):262-73. PubMed ID: 12482167
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Mitochondrial dysfunction in ALS.
    Cozzolino M, Carrì MT.
    Prog Neurobiol; 2012 May 15; 97(2):54-66. PubMed ID: 21827820
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient.
    Shook SJ, Pioro EP.
    Ann Neurol; 2009 Jan 15; 65 Suppl 1():S10-6. PubMed ID: 19191305
    [Abstract] [Full Text] [Related]

  • 49. Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS.
    Drechsel DA, Estévez AG, Barbeito L, Beckman JS.
    Neurotox Res; 2012 Nov 15; 22(4):251-64. PubMed ID: 22488161
    [Abstract] [Full Text] [Related]

  • 50. Amyotrophic lateral sclerosis.
    Mitchell JD, Borasio GD.
    Lancet; 2007 Jun 16; 369(9578):2031-2041. PubMed ID: 17574095
    [Abstract] [Full Text] [Related]

  • 51. Management of amyotrophic lateral sclerosis.
    Corcia P, Meininger V.
    Drugs; 2008 Jun 16; 68(8):1037-48. PubMed ID: 18484797
    [Abstract] [Full Text] [Related]

  • 52. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence.
    Sathasivam S, Ince PG, Shaw PJ.
    Neuropathol Appl Neurobiol; 2001 Aug 16; 27(4):257-74. PubMed ID: 11532157
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Antiglutamate therapy of ALS--which is the next step?
    Ludolph AC, Meyer T, Riepe MW.
    J Neural Transm Suppl; 1999 Aug 16; 55():79-95. PubMed ID: 10335495
    [Abstract] [Full Text] [Related]

  • 56. Translating preclinical insights into effective human trials in ALS.
    DiBernardo AB, Cudkowicz ME.
    Biochim Biophys Acta; 2006 Aug 16; 1762(11-12):1139-49. PubMed ID: 16713196
    [Abstract] [Full Text] [Related]

  • 57. Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention.
    Cunha-Oliveira T, Montezinho L, Mendes C, Firuzi O, Saso L, Oliveira PJ, Silva FSG.
    Oxid Med Cell Longev; 2020 Aug 16; 2020():5021694. PubMed ID: 33274002
    [Abstract] [Full Text] [Related]

  • 58. Developmental biology. Neuron research leaps ahead.
    Brown RH.
    Science; 2008 Aug 29; 321(5893):1169-70. PubMed ID: 18755965
    [No Abstract] [Full Text] [Related]

  • 59. Amyotrophic lateral sclerosis: progress and prospects for treatment.
    Dib M.
    Drugs; 2003 Aug 29; 63(3):289-310. PubMed ID: 12534333
    [Abstract] [Full Text] [Related]

  • 60. Disease-modifying therapies in amyotrophic lateral sclerosis.
    Chiò A, Mazzini L, Mora G.
    Neuropharmacology; 2020 May 01; 167():107986. PubMed ID: 32062193
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.